13 February 2015
UCLB is pleased to announce the appointment of David Hunter as Chairman with effect from 20th January 2015. David Hunter will succeed David Dutton, a founder of UCLB, who will remain on the board as a non-executive director having served as Chairman since 1994. UCLB is also welcoming to the board Professor Geraint Rees, Dean of the UCL Faculty of Life Sciences as a non-executive director.
David Hunter qualified as a chartered accountant with PWC before joining 3i, the FT100 listed private equity group where he became Managing Director of Investment Management responsible for the entire UK portfolio of assets. David’s current interests in venture and social investment include membership of Bridges Ventures’ Investment Committee for one of their socially orientated funds and non- executive director & Chair of the Audit Committee of a listed venture capital trust. In the not-for-profit area, David has been a Trustee of Age UK since 2012 and is Chairman of Age UK’s Audit and Risk Committee and is Chairman of the Investment Committee at Paragon, a large South West London housing association. David is an alumni of UCL having read Economics prior to joining the Institute of Chartered Accountants.
David Dutton commented, “I am delighted that the board has appointed David Hunter to succeed me as Chairman. I am grateful to Cengiz Tarhan and the other board members for all the effort they have put into UCLB during my time as Chairman. Throughout the years the board have seen the company grow from strength to strength and I look forward to working with David Hunter”.
David Hunter commented, “I am honoured to be appointed as Chairman of this great company. I am delighted that David Dutton is continuing on the Board as his expertise and knowledge of UCLB is endless. I look forward to working with UCLB and the Board going forward to continue growing the company with a strong flow of commercialisations from UCL’s world leading research base.”
Cengiz Tarhan, Managing Director of UCLB, said: “David Dutton has been instrumental in raising the profile of UCLB technology transfer activities. His personal involvement as a founder and his support for our activities has been immense. He has been the Chairman for over 20 years since we were Freemedic, through the UCL BioMedica period and as UCL Business. I am delighted that David Hunter is succeeding David Dutton as Chairman, he has an outstanding track record and I am sure he is the right person to lead the board in the future. I am also very pleased to be able to say that David Dutton is staying on the board as a non-executive director and I look forward to continue working with him and David Hunter in the future.”
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.
For further information, please visit: www.uclb.com